SMT202300482T1 - Animali non umani aventi un cluster umanizzato di un gene di differenziazione 47 - Google Patents

Animali non umani aventi un cluster umanizzato di un gene di differenziazione 47

Info

Publication number
SMT202300482T1
SMT202300482T1 SM20230482T SMT202300482T SMT202300482T1 SM T202300482 T1 SMT202300482 T1 SM T202300482T1 SM 20230482 T SM20230482 T SM 20230482T SM T202300482 T SMT202300482 T SM T202300482T SM T202300482 T1 SMT202300482 T1 SM T202300482T1
Authority
SM
San Marino
Prior art keywords
differentiation
gene
human animals
humanized
cluster
Prior art date
Application number
SM20230482T
Other languages
English (en)
Italian (it)
Inventor
Gavin Thurston
Cagan Gurer
Ella Ioffe
Alexander Mujica
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54979926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202300482(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT202300482T1 publication Critical patent/SMT202300482T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
SM20230482T 2014-12-05 2015-11-25 Animali non umani aventi un cluster umanizzato di un gene di differenziazione 47 SMT202300482T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087992P 2014-12-05 2014-12-05
EP20215046.2A EP3850946B1 (en) 2014-12-05 2015-11-25 Non-human animals having a humanized cluster of differentiation 47 gene

Publications (1)

Publication Number Publication Date
SMT202300482T1 true SMT202300482T1 (it) 2024-01-10

Family

ID=54979926

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20230482T SMT202300482T1 (it) 2014-12-05 2015-11-25 Animali non umani aventi un cluster umanizzato di un gene di differenziazione 47
SM20190178T SMT201900178T1 (it) 2014-12-05 2015-11-25 Animali diversi dall’uomo aventi un gruppo umanizzato del gene 47 di differenziazione
SM20210281T SMT202100281T1 (it) 2014-12-05 2015-11-25 Animali non umani aventi un cluster umanizzato di un gene di differenziazione

Family Applications After (2)

Application Number Title Priority Date Filing Date
SM20190178T SMT201900178T1 (it) 2014-12-05 2015-11-25 Animali diversi dall’uomo aventi un gruppo umanizzato del gene 47 di differenziazione
SM20210281T SMT202100281T1 (it) 2014-12-05 2015-11-25 Animali non umani aventi un cluster umanizzato di un gene di differenziazione

Country Status (29)

Country Link
US (5) US20160345549A1 (enExample)
EP (4) EP4296278B1 (enExample)
JP (2) JP6730277B2 (enExample)
KR (3) KR102313073B1 (enExample)
CN (2) CN107205368B (enExample)
AR (1) AR102888A1 (enExample)
AU (2) AU2015355328B2 (enExample)
BR (1) BR112017010490A2 (enExample)
CA (1) CA2967834C (enExample)
CY (2) CY1121547T1 (enExample)
DK (3) DK3466255T3 (enExample)
ES (3) ES2716735T3 (enExample)
FI (1) FI3850946T3 (enExample)
HR (3) HRP20190634T1 (enExample)
HU (3) HUE054661T2 (enExample)
IL (2) IL286403B2 (enExample)
LT (3) LT3850946T (enExample)
MX (1) MX2017007293A (enExample)
NZ (2) NZ769992A (enExample)
PL (3) PL3086637T3 (enExample)
PT (3) PT3850946T (enExample)
RS (3) RS58536B1 (enExample)
RU (1) RU2728412C2 (enExample)
SG (2) SG10202103050YA (enExample)
SI (3) SI3466255T1 (enExample)
SM (3) SMT202300482T1 (enExample)
TR (1) TR201903891T4 (enExample)
TW (1) TWI681053B (enExample)
WO (1) WO2016089692A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017010490A2 (pt) 2014-12-05 2018-04-03 Regeneron Pharma roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
ES2841353T3 (es) 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
US11284607B2 (en) * 2015-03-24 2022-03-29 The Trustees Of Columbia University In The City Of New York Genetic modification of pigs for xenotransplantation
AU2016270587B2 (en) 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
CN108366548B (zh) 2015-11-20 2021-10-08 瑞泽恩制药公司 具有人源化淋巴细胞活化基因3的非人动物
WO2017136712A1 (en) 2016-02-04 2017-08-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
US20190183101A1 (en) * 2016-08-11 2019-06-20 The Jackson Laboratory Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041121A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
MX381216B (es) * 2016-09-30 2025-03-12 Regeneron Pharma Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72.
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
CN108588126B (zh) * 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
WO2018177441A1 (en) 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
CN110869494B (zh) * 2017-06-12 2025-02-18 西奈卫生系统公司 无需全身性免疫遏制的同种异体移植物耐受
MX2020001309A (es) 2017-08-02 2020-08-20 Phanes Therapeutics Inc Anticuerpos anti-cd47 y sus usos.
JP7361031B2 (ja) * 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
IL277355B2 (en) * 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
CA3098040A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3123102A1 (en) 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
WO2020131632A1 (en) 2018-12-20 2020-06-25 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
WO2020147829A1 (zh) * 2019-01-17 2020-07-23 北京百奥赛图基因生物技术有限公司 人源化转基因动物
US20220312749A1 (en) * 2019-08-09 2022-10-06 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il2ra
CN112553252B (zh) * 2019-09-06 2022-04-29 百奥赛图(北京)医药科技股份有限公司 Tnfr2基因人源化的非人动物的构建方法和应用
CN113122574A (zh) * 2019-12-31 2021-07-16 百奥赛图(北京)医药科技股份有限公司 一种免疫缺陷型人源化非人动物的构建方法
CN112080522A (zh) * 2020-09-15 2020-12-15 广东药康生物科技有限公司 一种cd47人源化小鼠模型的构建方法
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
WO2023046061A1 (en) * 2021-09-24 2023-03-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric trop2
US20240102045A1 (en) 2022-07-19 2024-03-28 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025171307A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP4637749B2 (ja) * 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
EP2064325B1 (en) * 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CN101668387A (zh) 2008-09-02 2010-03-10 鸿富锦精密工业（深圳）有限公司 印刷电路板
CN102281758B (zh) * 2009-01-16 2014-12-10 公益财团法人实验动物中央研究所 移植了人肝细胞的小鼠
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011020014A1 (en) 2009-08-14 2011-02-17 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
SI2477648T1 (sl) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Sinergijska terapija proti CD47 za krvne rake
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
RS63220B1 (sr) 2011-10-28 2022-06-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
KR102295746B1 (ko) 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
SI2818478T1 (sl) 2011-10-28 2017-07-31 Regeneron Pharmaceuticals, Inc. Humanizirani il-6 in receptor il-6
EP2644027A1 (en) * 2012-03-26 2013-10-02 Institut Pasteur Transgenic immunodefficient mouse expressing human SIRPalpha.
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
KR102241962B1 (ko) 2012-09-07 2021-04-20 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
DK4389764T3 (da) * 2012-11-05 2026-04-13 Regeneron Pharma Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
US9848587B2 (en) 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
SI2958937T1 (sl) 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
HRP20231121T1 (hr) 2013-09-23 2023-12-22 Regeneron Pharmaceuticals, Inc. Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale
JP6492095B2 (ja) 2013-10-15 2019-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ｉｌ−１５動物
US20150143559A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
RS60398B1 (sr) 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
NO2785538T3 (enExample) 2014-05-07 2018-08-04
EP3482629B1 (en) 2014-05-19 2020-11-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals expressing human epo
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
BR112017010793A2 (pt) 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
BR112017010490A2 (pt) 2014-12-05 2018-04-03 Regeneron Pharma roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.

Also Published As

Publication number Publication date
AU2015355328A1 (en) 2017-05-18
US20240138384A1 (en) 2024-05-02
AU2015355328B2 (en) 2022-03-10
WO2016089692A1 (en) 2016-06-09
JP2020168016A (ja) 2020-10-15
SI3086637T1 (sl) 2019-04-30
US20210161112A1 (en) 2021-06-03
PL3466255T3 (pl) 2021-08-09
CN112342197A (zh) 2021-02-09
SMT202100281T1 (it) 2021-07-12
DK3466255T3 (da) 2021-05-03
SG10202103050YA (en) 2021-05-28
HUE054661T2 (hu) 2021-09-28
TWI681053B (zh) 2020-01-01
PL3086637T3 (pl) 2019-09-30
EP3086637A1 (en) 2016-11-02
HUE043132T2 (hu) 2019-07-29
CN107205368B (zh) 2020-11-17
KR102508175B1 (ko) 2023-03-09
EP3850946A1 (en) 2021-07-21
JP7089554B2 (ja) 2022-06-22
RS58536B1 (sr) 2019-04-30
PT3086637T (pt) 2019-03-26
CN112342197B (zh) 2025-02-18
HUE064960T2 (hu) 2024-04-28
DK3850946T5 (da) 2024-08-19
ES2716735T3 (es) 2019-06-14
RS61774B1 (sr) 2021-05-31
IL286403A (en) 2021-10-31
SG11201703463WA (en) 2017-05-30
KR20230038599A (ko) 2023-03-20
TW201629210A (zh) 2016-08-16
ES2969389T3 (es) 2024-05-17
SI3850946T1 (sl) 2024-02-29
BR112017010490A2 (pt) 2018-04-03
KR102313073B1 (ko) 2021-10-18
US20180249689A1 (en) 2018-09-06
AU2022203787A1 (en) 2022-06-23
IL286403B2 (en) 2023-10-01
NZ769992A (en) 2024-11-29
MX2017007293A (es) 2018-03-12
LT3086637T (lt) 2019-04-10
US10939673B2 (en) 2021-03-09
AU2022203787B2 (en) 2025-01-30
CY1121547T1 (el) 2020-05-29
US20160345549A1 (en) 2016-12-01
EP3466255B1 (en) 2021-02-17
AR102888A1 (es) 2017-03-29
IL252019A0 (en) 2017-06-29
RU2017123357A3 (enExample) 2019-06-03
EP4296278A2 (en) 2023-12-27
FI3850946T3 (fi) 2023-12-28
PT3850946T (pt) 2024-01-02
CN107205368A (zh) 2017-09-26
SMT201900178T1 (it) 2019-05-10
CA2967834A1 (en) 2016-06-09
ES2870462T3 (es) 2021-10-27
US12389889B2 (en) 2025-08-19
LT3850946T (lt) 2024-01-10
IL252019B (en) 2021-10-31
HRP20210662T1 (hr) 2021-05-28
RU2728412C2 (ru) 2020-07-29
DK3086637T3 (en) 2019-04-08
EP3466255A1 (en) 2019-04-10
JP6730277B2 (ja) 2020-07-29
KR20170098800A (ko) 2017-08-30
US11910788B2 (en) 2024-02-27
LT3466255T (lt) 2021-05-25
HK1225912A1 (en) 2017-09-22
KR102617691B1 (ko) 2023-12-27
DK3850946T3 (da) 2024-01-08
EP3850946B1 (en) 2023-09-27
HRP20190634T1 (hr) 2019-08-09
HRP20231707T1 (hr) 2024-03-15
US10015953B2 (en) 2018-07-10
US20160157470A1 (en) 2016-06-09
RS64989B1 (sr) 2024-01-31
JP2018500012A (ja) 2018-01-11
PT3466255T (pt) 2021-05-10
KR20210127773A (ko) 2021-10-22
TR201903891T4 (tr) 2019-04-22
PL3850946T3 (pl) 2024-03-11
CY1124089T1 (el) 2022-05-27
RU2017123357A (ru) 2019-01-09
CA2967834C (en) 2024-01-16
NZ731471A (en) 2021-12-24
IL286403B1 (en) 2023-06-01
EP3086637B1 (en) 2019-01-02
SI3466255T1 (sl) 2021-07-30
EP4296278B1 (en) 2026-06-17
EP4296278A3 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
IL282649A (en) Non-human animals with a humanized gene for differentiation cluster 274
IL286403A (en) Non-human animals having a humanized cluster of differentiation 47 gene
IL287519A (en) Non-human animals with a humanized programmed cell death gene 1
IL258841B (en) Non-human animals with human lymphocyte activation gene 3